All In Biotech

Drug Trial Radar · NCT05546476

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 187 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

187

Actual

Start

Nov 21, 2022

Primary completion

Mar 13, 2024

Study completion Apr 23, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

Conditions

  • Non-small Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Loss of Appetite
  • Fatigue
  • Cachexia

Interventions

  • ponsegromabDrug

    Double-Blind ponsegromab Treatment followed by Open Label ponsegromab Treatment

  • Placebo for ponsegromabDrug

    Double-Blind placebo Treatment followed by Open Label ponsegromab Treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Change From Baseline in Body Weight at Week 12Time frame: Baseline, Week 12

Locations

78 sites in 11 countries. Site status is shown where the registry gives one.

  • CARTI Conway

    Conway, Arkansas

  • CARTI Cancer Center

    Little Rock, Arkansas

  • CARTI North Little Rock

    North Little Rock, Arkansas

  • CARTI Stuttgart

    Stuttgart, Arkansas

  • Pacific Cancer Medical Center INC

    Anaheim, California

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Emad Ibrahim,MD,INC.

    Redlands, California

  • Providence Medical Foundation

    Santa Rosa, California

  • IU Health Arnett Cancer Center

    Lafayette, Indiana

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana

  • Tandem Clinical Research

    Marrero, Louisiana

  • Bozeman Health Deaconess Hospital

    Bozeman, Montana

  • Oregon Health and Science University: Center for Health and Healing 1

    Portland, Oregon

  • Oregon Health and Science University: Center for Health and Healing 2

    Portland, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Carta - Clinical Associates in Research Therapeutics of America, LLC

    San Antonio, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

  • Wenatchee Valley Hospital

    Wenatchee, Washington

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Orange Hospital

    Orange, New South Wales, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Western Health-Sunshine & Footscray Hospitals

    St Albans, Victoria, Australia

  • Complex Oncology Center - Burgas

    Burgas, Bulgaria

  • Specialized Hospital for Active Treatment of Oncology - Haskovo

    Haskovo, Bulgaria

  • Complex Oncology Center - Ruse EOOD

    Rousse, Bulgaria

  • Complex Oncology Center - Shumen

    Shumen, Bulgaria

  • Multiprofile Hospital for Active Treatment Serdika EOOD

    Sofia, Bulgaria

  • MHAT for Women's Health Nadezhda

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Sofiamed

    Sofia, Bulgaria

  • Complex Oncology Center - Vratsa

    Vratsa, Bulgaria

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • CIUSSS- saguenay-Lac-Saint-Jean

    Chicoutimi, Quebec, Canada

  • Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski

    Rimouski, Quebec, Canada

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Changzhou No.2 People's Hospital

    Changzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.